S. Amin

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Samuel E. Donovan, G. Getz, V. Mootha, 2018, Cancer cell.

Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer

G. Freeman, D. Zurakowski, S. Parangi, 2016, Oncotarget.

Anti‐PD‐1/PD‐L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer

G. Freeman, A. Alessandrini, S. Parangi, 2019, International journal of cancer.

Inhibition of MAPKinase pathway sensitizes thyroid cancer cells to ABT-737 induced apoptosis.

S. Parangi, K. Sarosiek, E. Brauner, 2017, Cancer letters.

Circulating BRAF V600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma

R. Sullivan, S. Parangi, C. Lubitz, 2018 .

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer

G. Freeman, A. Alessandrini, S. Parangi, 2018, British Journal of Cancer.

Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

R. Sullivan, S. Parangi, C. Lubitz, 2018, Thyroid : official journal of the American Thyroid Association.

Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer

A. Alessandrini, S. Parangi, Benjamin Gigliotti, 2018, British Journal of Cancer.

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Samuel E. Donovan, G. Getz, V. Mootha, 2018, Cancer cell.